论文部分内容阅读
目的:探讨纤溶功能在高血压、肿瘤、脑血管病变、慢性阻塞性肺部疾病及肾病患者中的变化及临床意义。方法:通过检测125例高血压患者、56例肿瘤患者、33例脑血管病变患者、50例COPD患者及56例肾病患者血浆t-PA的水平对照组进行比较。结果:各疾病组t-PA较正常组降低,有统计学意义(P<0.05)。结论高血压、肿瘤,脑血管病变,慢性阻塞性肺部疾病患者都伴有内源性纤溶功能的减退,提示常规检测t-PA,以能及时了解各系统疾病的异常,对患者病程发展进行较为准确的评价的评价:早期使用t-PA可能是预防性治疗栓赛性疾病的理想药物。
Objective: To investigate the changes and clinical significance of fibrinolytic function in patients with hypertension, tumor, cerebrovascular disease, chronic obstructive pulmonary disease and nephropathy. Methods: Plasma t-PA levels in 125 hypertensive patients, 56 cancer patients, 33 patients with cerebrovascular disease, 50 patients with COPD and 56 patients with nephropathy were compared. Results: The levels of t-PA in all disease groups were lower than those in normal group (P <0.05). Conclusions Patients with hypertension, tumor, cerebrovascular disease and chronic obstructive pulmonary disease are accompanied by the decline of endogenous fibrinolytic function, suggesting routine testing of t-PA in order to understand the abnormalities of various systemic diseases in time, Evaluation of a More Accurate Evaluation: Early use of t-PA may be the ideal prophylaxis for thrombotic disorders.